Human Albumin Grifols

Human Albumin Grifols is a sterile solution for injection containing human serum albumin as the active ingredient. It is supplied in a standard concentration for intravenous administration and is marketed in the European Union as a prescription‑only plasma protein used to restore circulatory volume. The product is indicated for conditions associated with low plasma oncotic pressure and is stored under controlled temperature conditions to maintain protein stability.

Human Albumin Grifols is employed in clinical settings where rapid expansion of intravascular volume is required.

- Treatment of hypovolemia due to trauma, surgery, or fluid loss. - Management of circulatory shock when other volume expanders are insufficient. - Support for patients with extensive burns to counteract protein loss. - Correction of hypoalbuminemia in liver disease, nephrotic syndrome, or malnutrition. - Adjunct therapy during plasma exchange procedures to maintain oncotic balance. - Use in cardiac surgery to stabilize hemodynamics during cardiopulmonary bypass.

Adverse reactions to Human Albumin Grifols are generally infrequent but can range from mild to severe.

Common: - Transient fever or chills during infusion. - Mild headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Localized erythema or swelling at the injection site. - Urticaria or rash. - Elevated blood pressure.

Serious: - Anaphylactic or severe allergic reaction. - Acute hemolysis. - Volume overload leading to pulmonary edema. - Hypercoagulable state or thromboembolic events. - Renal dysfunction due to increased plasma viscosity. - Sepsis from contaminated product.

Clinicians should observe specific precautions when prescribing Human Albumin Grifols to minimize risk and ensure therapeutic benefit.

- Assess volume status and cardiac function before administration. - Avoid use in patients with known hypersensitivity to human albumin or blood products. - Monitor for signs of fluid overload, especially in heart failure or renal impairment. - Use caution in patients with severe liver disease or coagulopathy. - Adjust dose in pediatric or geriatric populations as needed. - Ensure product integrity; discard if vial is compromised. - Check serum albumin levels to guide necessity of replacement therapy.

Human Albumin Grifols can interact with other medications or clinical conditions, influencing safety or efficacy.

Avoid: - Concurrent administration with high‑dose diuretics that may exacerbate hypovolemia. - Use with other plasma expanders that increase risk of volume overload. - Co‑infusion with blood products that are not screened for compatibility.

Use with caution: - Concurrent anticoagulants, as albumin may alter drug binding and affect coagulation monitoring. - Vasopressor agents; volume expansion may modify hemodynamic response. - Renal replacement therapies, which can affect albumin clearance. - Immunosuppressive drugs, because albumin can serve as a carrier and modify distribution.